Compare PEGA & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEGA | SRRK |
|---|---|---|
| Founded | 1983 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 6.8B |
| IPO Year | 1996 | 2018 |
| Metric | PEGA | SRRK |
|---|---|---|
| Price | $32.39 | $52.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | ★ $60.13 | $56.17 |
| AVG Volume (30 Days) | ★ 2.2M | 1.5M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | ★ 91.89 | N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $682,695,000.00 | N/A |
| Revenue This Year | $15.99 | N/A |
| Revenue Next Year | $11.90 | $534.24 |
| P/E Ratio | $182.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.66 | $27.07 |
| 52 Week High | $68.10 | $58.49 |
| Indicator | PEGA | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 51.57 | 51.66 |
| Support Level | $32.00 | $51.32 |
| Resistance Level | $38.18 | $58.49 |
| Average True Range (ATR) | 1.43 | 2.48 |
| MACD | 0.33 | -0.49 |
| Stochastic Oscillator | 76.98 | 30.08 |
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.